Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All favipiravir studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchFavipiravirFavipiravir (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Paxlovid Meta
Famotidine Meta Quercetin Meta
Favipiravir Meta Remdesivir Meta
Fluvoxamine Meta Thermotherapy Meta
Hydroxychlor.. Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Effect of favipiravir use on INR, PT, aPTT tests of COVID-19 patients

Gül et al., Sabuncuoglu Serefeddin Health Sciences, doi:10.55895/sshs.1213382
Jan 2023  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Retrospective 100 patients in Turkey analyzing the effects of favipiravir on coagulation parameters in COVID-19 patients. Results showed prothrombin time (PT) and international normalized ratio (INR) were significantly prolonged in the favipiravir group, indicating impaired clotting ability. However, no difference was seen in activated partial thromboplastin time (aPTT) between groups. The authors conclude favipiravir prolongs clotting time, which could increase bleeding risk. They recommend close monitoring of coagulation and potential dosage adjustments of anticoagulants in COVID-19 patients receiving favipiravir. Further research is needed to confirm the coagulation effects of this antiviral medication.
Gül et al., 3 Jan 2023, retrospective, Turkey, peer-reviewed, 4 authors, study period June 2021 - March 2022. Contact: mehmetali.gul@amasya.edu.tr.
This PaperFavipiravirAll
EFFECT OF FAVIPIRAVIR USE ON INR, PT, APTT TESTS OF COVID-19 PATIENTS
Mehmet Ali Gul, Nezahat Kurt, Mustafa Capraz, Alpaslan Ozturk
The 2019 coronavirus disease (COVID-19) has caused millions of cases worldwide. As the pandemic progresses, understanding the effects of this disease remains important. We aimed to examine the hematological effects of the disease. The research was carried out as a retrospective study, 50 patients using favipiravir and 50 patients not using favipiravir who had positive COVID-19 RT-PCR test in nasal and throat swabs were included in the study. INR, PTT, aPTT tests were evaluated on all patients. Results of patients using favipiravir; INR 1.3±0.2, PT(s) 16.4±3.4, aPTT(s) 40.7±10.1, while the results of patients who did not use favipiravir were INR 1,2±0.2, PT(s) 14.6±2.5, aPTT(s) was found 38.4±7.8. While PT and INR were found to significantly higher in patients using favipiravir (p<0.05), the elevation in aPTT values was not significant. As a consequence, it was obtained that favipiravir prolongs the clotting time. In the light of these results, it is recommended to consider this in anticoagulant therapy used for treatment.
Information This study was presented as an oral presentation at the VII. Turkey In Vitro Diagnostics (IVD) Symposium 2022. We would like to thank the staff and doctors of Sabuncuoğlu Şerefeddin Training and Research Hospital (especially laboratories and clinics related to COVID-19), who worked with great dedication. Conflicts of interest The authors declare that there are no potential conflicts of interest relevant to this article. Gul M. A., Kurt N., Capraz M., Ozturk A. (2022) . Effect of Favipiravir Use on INR, PT, aPTT Tests of 4(3), [14] [15] [16] [17] [18] [19] [20]
References
Akbari, Tabrizi, Lankarani, Aria, Vakili et al., The role of cytokine profile and lymphocyte subsets in the severity of coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis, Life Sciences, doi:10.1016/j.lfs.2020.118167
Atçalı, Yakut, Çağlayan, Ulucan, Kara, Effects of favipiravir on hematologic parameters and bone marrow in the rats, Journal of Experimental and Clinical Medicine
Bert, Tan, Kunasegaran, Tham, Hafezi et al., SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls, Nature, doi:10.1038/s41586-020-2550-z
Ciaccio, Agnello, Biochemical biomarkers alterations in Coronavirus Disease 2019 (COVID-19), Diagnosis (Berl), doi:10.1515/dx-2020-0057
Connors, Levy, COVID-19 and its implications for thrombosis and anticoagulation, Blood, doi:10.1182/blood.2020006000
Conway, Mackman, Warren, Wolberg, Mosnier et al., Understanding COVID-19-associated coagulopathy, Nat Rev Immunol, doi:10.1038/s41577-022-00762-9
De Clercq, New Nucleoside Analogues for the Treatment of Hemorrhagic Fever Virus Infections, Chem Asian J, doi:10.1002/asia.201900841
Furuta, Komeno, Nakamura, Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase, Proc Jpn Acad Ser B Phys Biol Sci, doi:10.2183/pjab.93.027
Gul, Kurt, Capraz, Ozturk, Effect of Favipiravir Use on INR, PT, aPTT Tests of COVID-19 Patients Sabuncuoglu, Serefeddin Health Science
Mir, Tahamtan, Nikoo, Arabi, Moradi et al., Evaluation of biochemical characteristics of 183 COVID-19 patients: A retrospective study, Gene Rep, doi:10.1016/j.genrep.2021.101448
Shang, Wan, Liu, Yount, Gully et al., Structure of mouse coronavirus spike protein complexed with receptor reveals mechanism for viral entry, PLoS Pathog, doi:10.1371/journal.ppat.1008392
Thachil, What do monitoring platelet counts in COVID-19 teach us, Journal of Thrombosis and Haemostasis, doi:10.1111/jth.14879
Wang, Zhong, Salam, Tarning, Zhan et al., Phase 2a, openlabel, dose-escalating, multi-center pharmacokinetic study of favipiravir (T-705) in combination with oseltamivir in patients with severe influenza, EBioMedicine, doi:10.1016/j.ebiom.2020.103125
Yang, Cao, Qin, Wang, Cheng et al., Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19):A multi-center study in Wenzhou city, Zhejiang, China, J Infect, doi:10.1016/j.jinf.2020.02.016
Yaylaci, Dheir, Senocak, Genc, Kocayigit et al., The effects of favipiravir on hematological parameters of covid-19 patients, Rev Assoc Med Bras, doi:10.1590/1806-9282.66.S2
Zhou, Yu, Du, Fan, Liu et al., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet, doi:10.1016/S0140-6736(20)30566-3
Zinellu, Paliogiannis, Carru, Mangoni, INR and COVID-19 severity and mortality: A systematic review with meta-analysis and meta-regression, Adv Med Sci, doi:10.1016/j.advms.2021.07.009
{ 'indexed': {'date-parts': [[2023, 6, 23]], 'date-time': '2023-06-23T07:41:01Z', 'timestamp': 1687506061140}, 'reference-count': 7, 'publisher': 'Amasya University', 'issue': '3', 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'accepted': {'date-parts': [[2022, 12, 19]]}, 'abstract': '<jats:p xml:lang="en">The 2019 coronavirus disease (COVID-19) has caused millions of cases ' 'worldwide. As the pandemic progresses, understanding the effects of this disease remains ' 'important. We aimed to examine the hematological effects of the disease. The research was ' 'carried out as a retrospective study, 50 patients using favipiravir and 50 patients not using ' 'favipiravir who had positive COVID-19 RT-PCR test in nasal and throat swabs were included in ' 'the study. INR, PTT, aPTT tests were evaluated on all patients. Results of patients using ' 'favipiravir; INR 1.3±0.2, PT(s) 16.4±3.4, aPTT(s) 40.7±10.1, while the results of patients ' 'who did not use favipiravir were INR 1,2±0.2, PT(s) 14.6±2.5, aPTT(s) was found 38.4±7.8. ' 'While PT and INR were found to significantly higher in patients using favipiravir ' '(p&amp;lt;0.05), the elevation in aPTT values was not significant. As a consequence, it was ' 'obtained that favipiravir prolongs the clotting time. In the light of these results, it is ' 'recommended to consider this in anticoagulant therapy used for treatment.</jats:p>', 'DOI': '10.55895/sshs.1213382', 'type': 'journal-article', 'created': { 'date-parts': [[2022, 12, 19]], 'date-time': '2022-12-19T08:38:41Z', 'timestamp': 1671439121000}, 'page': '14-20', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Effect of favipiravir use on INR, PT, aPTT tests of COVID-19 patients', 'prefix': '10.55895', 'volume': '4', 'author': [ { 'ORCID': 'http://orcid.org/0000-0002-5849-0116', 'authenticated-orcid': True, 'given': 'Mehmet Ali', 'family': 'GÜL', 'sequence': 'first', 'affiliation': [{'name': 'AMASYA ÜNİVERSİTESİ, TIP FAKÜLTESİ'}]}, { 'ORCID': 'http://orcid.org/0000-0002-1685-5332', 'authenticated-orcid': True, 'given': 'Nezahat', 'family': 'KURT', 'sequence': 'additional', 'affiliation': [{'name': 'Erzincan Binali Yıldırım Üniversitesi Tıp Fakültesi'}]}, { 'ORCID': 'http://orcid.org/0000-0001-9586-6509', 'authenticated-orcid': True, 'given': 'Mustafa', 'family': 'ÇAPRAZ', 'sequence': 'additional', 'affiliation': [{'name': 'AMASYA ÜNİVERSİTESİ, TIP FAKÜLTESİ'}]}, { 'ORCID': 'http://orcid.org/0000-0003-4525-3477', 'authenticated-orcid': True, 'given': 'Alpaslan', 'family': 'ÖZTÜRK', 'sequence': 'additional', 'affiliation': [ { 'name': 'Sağlık Bilimleri Üniversitesi, Ankara Dışkapı Yıldırım Beyazıt ' 'Eğitim ve Araştırma Hastanesi,'}]}], 'member': '7009', 'published-online': {'date-parts': [[2023, 1, 3]]}, 'reference': [ { 'key': 'ref1', 'doi-asserted-by': 'crossref', 'unstructured': 'Ciaccio, M., & Agnello, L. (2020). Biochemical biomarkers alterations in ' 'Coronavirus Disease 2019 \r\n' '(COVID-19). Diagnosis (Berl), 7(4), 365-372. doi:10.1515/dx-2020-0057', 'DOI': '10.1515/dx-2020-0057'}, { 'key': 'ref2', 'doi-asserted-by': 'crossref', 'unstructured': 'Connors, J. M., & Levy, J. H. (2020). COVID-19 and its implications for ' 'thrombosis and \r\n' 'anticoagulation. Blood, 135(23), 2033-2040. doi:10.1182/blood.2020006000', 'DOI': '10.1182/blood.2020006000'}, { 'key': 'ref3', 'doi-asserted-by': 'crossref', 'unstructured': 'Conway, E. M., Mackman, N., Warren, R. Q., Wolberg, A. S., Mosnier, L. ' 'O., Campbell, R. A., . . . \r\n' 'Morrissey, J. H. (2022). Understanding COVID-19-associated coagulopathy. ' 'Nat Rev Immunol, \r\n' '22(10), 639-649. doi:10.1038/s41577-022-00762-9', 'DOI': '10.1038/s41577-022-00762-9'}, { 'key': 'ref4', 'doi-asserted-by': 'crossref', 'unstructured': 'Mir, S. M., Tahamtan, A., Nikoo, H. R., Arabi, M. S., Moradi, A. W., ' 'Ardakanian, S., & Tabarraei, A. \r\n' '(2022). Evaluation of biochemical characteristics of 183 COVID-19 ' 'patients: A retrospective \r\n' 'study. Gene Rep, 26, 101448. doi:10.1016/j.genrep.2021.101448', 'DOI': '10.1016/j.genrep.2021.101448'}, { 'key': 'ref5', 'doi-asserted-by': 'crossref', 'unstructured': 'Thachil, J. (2020). What do monitoring platelet counts in COVID-19 teach ' 'us? Journal of \r\n' 'Thrombosis and Haemostasis, 18(8), 2071-2072. doi:10.1111/jth.14879', 'DOI': '10.1111/jth.14879'}, { 'key': 'ref6', 'doi-asserted-by': 'crossref', 'unstructured': 'Tuğçe Atcali , S. Y., Cüneyt Çağlayan , Aykut Ulucan , Adem Kara. ' '(2021). Effects of favipiravir on \r\n' 'hematologic parameters and bone marrow in the rats. J Exp Clin Med, ' '39(1), 156-159.', 'DOI': '10.52142/omujecm.39.1.31'}, { 'key': 'ref7', 'doi-asserted-by': 'crossref', 'unstructured': 'Yaylaci, S., Dheir, H., Senocak, D., Genc, A. B., Kocayigit, H., Cekic, ' 'D., . . . Karabay, O. (2020). The \r\n' 'effects of favipiravir on hematological parameters of covid-19 patients. ' 'Rev Assoc Med Bras \r\n' '(1992), 66Suppl 2(Suppl 2), 65-70. doi:10.1590/1806-9282.66.S2.65\r\n' 'Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., . . . Cao, B. ' '(2020). Clinical course and risk factors for \r\n' 'mortality of adult inpatients with COVID-19 in Wuhan, China: a ' 'retrospective cohort study. \r\n' 'Lancet, 395(10229), 1054-1062. doi:10.1016/S0140-6736(20)30566-3', 'DOI': '10.1590/1806-9282.66.s2.65'}], 'container-title': 'Sabuncuoglu Serefeddin Health Sciences', 'original-title': [], 'deposited': { 'date-parts': [[2023, 6, 22]], 'date-time': '2023-06-22T04:11:08Z', 'timestamp': 1687407068000}, 'score': 1, 'resource': {'primary': {'URL': 'http://dergipark.org.tr/en/doi/10.55895/sshs.1213382'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2023, 1, 3]]}, 'references-count': 7, 'journal-issue': {'issue': '3', 'published-online': {'date-parts': [[2023, 1, 3]]}}, 'URL': 'http://dx.doi.org/10.55895/sshs.1213382', 'relation': {}, 'ISSN': ['2667-6338'], 'published': {'date-parts': [[2023, 1, 3]]}}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit